Citations

Clear

361 citation(s) found for "Bauer, M".

Fulminant Cerebral Edema From Hyperammonemia in Alpha-1-antitrypsin Deficiency Related Cirrhosis and Adynamic Ileus After Gastrointestinal Bleeding
Al-Asaad, Abdullah , Rigby, Mark , Bhatt, S., Bauer, Philippe R.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3885-A3885

10.1164/ajrccm.2025.211.abstracts.a3885 Get It

Abstract Background Intracranial hypertension from cerebral edema is a feared complication in patients with acute liver failure. Diagnosing cerebral edema in critically ill patients can be challenging as it may be insidious in onset. We present a case of fulminant hyperammonemia-induced cerebral edema in a patient with newly diagnosed alpha-1-antitrypsin deficiency (A1AD) in the setting of intestinal ileus and ineffective lactulose therapy. Case A 48-year-old male with newly diagnosed A1AD-related cirrhosis, alcohol use, and obesity (BMI 48.9) presented at an outside facility with altered mental status. Physical exam showed waxing and waning mentation, and serum ammonia was 245 mcmol/L. Upon transfer to our facility, hemoglobin was 10.3 g/dL, creatinine 1.77 mg/dL, total bilirubin 1.5 mg/dL, INR 1.2, ALT 60 U/L, AST 107 U/L, ALP 173 U/L, and serum ammonia 138 mcmol/L. Serum alpha-1-antitrypsin returned at 41 mg/dL with SZ phenotype. Abdominal ultrasound showed cirrhosis with moderate ascites. Paracentesis demonstrated no acute peritonitis. After initiation of lactulose and rifaximin, his mental status improved initially. However, he experienced 2 episodes of coffee-ground emesis with hemoglobin dropping to 7.0 g/dL requiring blood transfusions. Urgent esophagogastroduodenoscopy, limited by large residual contents, found no active bleed. A nasogastric tube was placed. CT abdomen pelvis showed diffuse colonic and small bowel dilation consistent with adynamic ileus impairing lactulose administration. His mental status worsened, necessitating ICU transfer and intubation for airway protection. Serum ammonia peaked at 397 mcmol/L. Neostigmine did not restore any effective bowel movement, and continuous renal replacement therapy was initiated to control the hyperammonemia. A convulsive episode prompted imaging. Head CT showed diffuse cerebral edema, later confirmed on MRI (Figure 1). Continuous electroencephalogram showed diffuse slowing without epileptiform discharges. His protracted hospital course was marked by minimal neurological recovery requiring tracheostomy and ongoing supportive measures per family wishes. Discussion Cerebral edema is one of the leading causes of morbidity and mortality in patients with severe hyperammonemia, which can result in irreversible cortical and deep grey matter injury that typically spares perirolandic and medial occipital regions. Although the exact mechanism continues to be researched elevated serum ammonia plays a critical role in disrupting the innate cerebral autoregulation. Prompt diagnosis and early intracranial pressure control (head of the bed elevation, hyperventilation, mannitol, hypertonic saline) are paramount. Typical hyperammonemia treatment includes lactulose, rifaximin, or polyethylene glycol, and correction of any precipitating factors. Dialysis should be considered early to prevent cerebral toxicity in hyperammonemia refractory to conventional treatments.
Bisphosphonates Trigger Anti-Ageing Effects Across Multiple Cell Types and Protect Against Senescence
Lu, Jinsen , Zhan, Haoqun, Gámez, Beatriz, Platt, Eleanor, Frost, Lucy R. , Allen, T. C., Marshall, Gayle , Huber, K. , Vendrell, Iolanda , Reid, Ian R. , Bountra, C. , Kirkland, James L. , Ebetino, Frank H. , Edwards, James , Huber, Kilian V M , Khosla, Sundeep , Rao, Srinivasa R. , Knowles, Helen J. , Zhan, Haoqun, Allen, Tiffany-Jayne, Bauer, Ludwig G. , Kessler, Benedikt Mathias , Horne, Anne M. , Khosla, Sundeep , Ej, Roldán , Russell, R.G.G.

Mayo Clinic

No container title available | March 26, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.03.25.645228 | PMID 40196558 Get It

Abstract Bisphosphonates (BPs) have been the major class of medicines used to treat disorders of excessive bone loss for over five decades. Recently it has been recognized that BPs may also have additional significant beneficial extra-skeletal effects. These include a reduction of all-cause mortality and of conditions commonly linked to ageing, such as cancer and cardiovascular disease. Here we show that bisphosphonates co-localize with lysosomal and endosomal organelles in non-skeletal cells and stimulate cell growth at low doses. In vivo spatial transcriptomic analysis revealed differentially expressed senescence markers in multiple organs of aged BP-treated mice, and a shift in cellular composition toward those of young counterparts. Similarly, a 5000-plex plasma proteome analysis from osteopenic patients before and after BP-treatment showed significant alterations in ∼400 proteins including GTPase regulators and markers of senescence, autophagy, apoptosis, and inflammatory responses. Furthermore, treatment with BPs protected against the onset of senescence in vitro . Proteome-wide target deconvolution using 2D thermal profiling revealed novel BP-binding targets (PHB2, ASAH1), and combined with RNA- and ATAC-seq of BP-treated cells and patient data, suggests downstream regulation of the MEF2A transcription factor within the heart. Collectively, these results indicate how BPs may beneficially modify the human plasma proteome, and directly impact multiple non-skeletal cell types through previously unidentified proteins, thereby influencing a range of pathways related to senescence and ageing.
PPM1M, a LRRK2-counteracting, phosphoRab12-preferring phosphatase with potential link to Parkinson’s disease
Chiang, Claire Y , Pratuseviciute, Neringa , Lin, Yu‐En , Adhikari, Ayan , Yeshaw, Wondwossen M , Flitton, Chloe , Sherpa, Pemba , Tonelli, Francesca , Lynch, Timothy , Siuda, Joanna , Pulyk, O. R. , Sherpa, Pemba L , Rektorova, Irena , Lynch, Timothy , Siuda, Joanna S. , Pulyk, Oleksandr , Bauer, Peter , Beetz, Christian , Dickson, Dennis W , Ross, Owen A , Wszolek, Z.K. , Klein, Christine , Zimprich, Alexander , Alessi, Dario R , Sammler, Esther M , Pfeffer, Suzanne R , Tonelli, Francesca , Rektorová, Irena , Rudzińska, Monika , Dickson, Dennis W. , Ross, Owen A. , Wszołek, Zbigniew K. , Klein, Christine , Zimprich, Alexander , Alessi, Dario R. , Sammler, Esther

Mayo Clinic

No container title available | March 21, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.03.19.644182 | PMID 40166354 Get It

Abstract Leucine-rich repeat kinase 2 (LRRK2) phosphorylates a subset of Rab GTPases that regulate receptor trafficking; activating mutations in LRRK2 are linked to Parkinson’s disease. Rab phosphorylation is a transient event that can be reversed by phosphatases, including PPM1H, that acts on phosphoRab8A and phosphoRab10. Here we report a phosphatome-wide siRNA screen that identified PPM1M as a phosphoRab12-preferring phosphatase that also acts on phosphoRab8A and phosphoRab10. Upon knockout from cells or mice, PPM1M displays selectivity for phosphoRab12. As shown previously for mice harboring LRRK2 pathway mutations, knockout of Ppm1m leads to primary cilia loss in striatal cholinergic interneurons. We have also identified a rare PPM1M mutation in patients with Parkinson’s disease that is catalytically inactive when tested in vitro and in cells. These findings identify PPM1M as a key player in the LRRK2 signaling pathway and provide a new therapeutic target for the possible benefit of patients with Parkinson’s disease. Teaser Parkinson’s linked Rab phosphorylation is reversed by PPM1M; the inactive D440N variant is implicated in rare patient cases.
Using a Wearable Brain Activity Sensing Device in the Treatment of Long COVID Symptoms in an Open-Label Clinical Trial
Ganesh, Ravindra , Schroeder, Darrell R. , Hanson, Jennifer L., Fokken, Shawn C. , Overgaard, Joshua , Bauer, Brent A. , Aakre, Christopher A. , Pruthi, Sandhya , Croghan, Ivana T. , Hurt, Ryan T. , Ganesh, Ravindra , Schroeder, Darrell , Overgaard, Joshua D, Thilagar, Bright P. , Croghan, Ivana T , Thilagar, Bright

Mayo Clinic

Journal of Primary Care & Community Health | March 12, 2025 | Volume: 16 | Issue: No issue available | Pages: No page available

10.1177/21501319251325639 | PMID 40071827 Get It

Objective: This study evaluated the feasibility and satisfaction of using a wearable brain activity sensing device for stress reduction among patients experiencing Long COVID (LC). Patients and Methods: Patients with LC (N = 45) were invited to participate in an open-label pilot study. Participants were asked to use a brain-sensing electroencephalogram (S-EEG) wearable device (Muse-S™) daily for 90 days and followed for an additional 90 days (180 days total participation). Study enrollment began June 28, 2022, and ended July 28, 2023. Results: Patients were predominantly female (82%), white (96%), and with an average age of 47.6 (±12.5) years. At the end of treatment (90 days), cognition, sleep, self-efficacy, and quality-of-life quality of life improved ( P < .001 to P = .04). In addition, stress and anxiety were significantly reduced ( P < .001). These significant changes persisted by end-of-study (180 days). For stress ( P = .023) and anxiety ( P = .033), a change from the baseline during follow-up was significantly associated with the amount of S-EEG usage. The end-of-study satisfaction survey indicated that patients were very satisfied with the S-EEG device, and 97% planned to continue using it. Conclusion: Results suggest that the S-EEG device improved cognition in LC, which is one of the main severe symptoms we see in our LC clinic. In addition, it helped reduce stress and anxiety. These findings have important clinical implications for LC patients using S-EEG as an adjunct to concurrent LC clinical care which includes pharmacotherapies.
Smart biomanufacturing for health equity in regenerative medicine therapies
Henn, Alicia D. , Wolff, Mark , Mitra, Kunal , Finger-Baker, Isaac, Yerden, Randy, Alm, Kersti , Finger-Baker, Isaac, Bauer, Steven R. , Terzic, André

Mayo Clinic

Regenerative Medicine Reports | March 10, 2025 | Volume: 2 | Issue: 1 | Pages: 31-35

10.4103/regenmed.regenmed-d-24-00021 Get It

Limited scalability and restricted affordability impede the equitable deployment of curative models of care despite advances achieved with regenerative medicine therapeutics. Mitigating the risk of widening health disparities mandates actions that would improve the availability and accessibility of new classes of biotherapeutics. Namely, the use of Smart Manufacturing empowered by artificial intelligence to increase therapeutic production capacity while reducing cost is an emerging strategy central to the future of the regenerative care economy. Establishing an efficient and effective biomanufacturing ecosystem is essential to building regenerative pipelines into broadly available regenerative therapeutics options. This ecosystem must provide not only necessary cell environment controls and computer process power, but also the sensing technologies to feed critical process parameters to the algorithms in real-time. Here we outline key elements that are in development to support Smart Biomanufacturing, such as machine learning, advanced analytics, digital twins, and modular cytocentric production. The aim of integrating these technologies is to drive down costs, improve access to new regenerative medicine therapeutics, address regulatory science expectations, and in doing so, improve health equity.
Effect of Reiki on Measures of Well-Being in Low-Income Patients with Mental Health Diagnoses
Prasad, Kavita, Drost, M., Baldwin, Ann L. , Soderlind, Jennifer N., Croghan, Ivana T. , Wahner‐Roedler, Dietlind L. , Bauer, Brent A. , St Sauver, Jennifer, Drost, Mitchell S, Croghan, Ivana T , Wahner-Roedler, Dietlind L , Bauer, Brent A , Dyer, Natalie L. , Sauver, Jennifer L. St. , Drost, Mitchell S., Prasad, Vikas, Hassan, Ahmed Nabeel

Mayo Clinic

Global Advances in Integrative Medicine and Health | March 4, 2025 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/27536130251323581 | PMID 40034577 Get It

Background More than 1 in 5 US adults live with mental illness. Novel therapies as complements to standard therapies are needed to improve patient well-being. Reiki is a biofield therapy that may improve well-being in mental health. Objective The primary aim of this study was to evaluate the feasibility of providing Reiki at a behavioral health clinic serving a low-income population. The secondary aim was to evaluate outcomes in terms of patients’ symptoms, emotions, and feelings before and after Reiki. Methods This was a mixed-methods, feasibility pilot study with a pre-post experimental design. Reiki was offered to adult outpatients at a community behavioral health center in Rochester, Minnesota. Patients with a stable mental health diagnosis seen between July 22, 2021, and May 18, 2023, completed surveys before and after the Reiki intervention and provided qualitative feedback. Patients were asked to report their ratings of pain, anxiety, fatigue, and feelings (eg, happy, calm) on 0- to 10-point numeric rating scales. Data were analyzed with Wilcoxon signed rank tests. Results Among 91 patients who completed a Reiki session during the study period, 74 (81%) were women. Major depressive disorder (71%), posttraumatic stress disorder (47%), and generalized anxiety disorder (43%) were the most common diagnoses. The study was feasible in terms of recruitment, retention, data quality, acceptability, and fidelity of the intervention. Patient ratings of pain, fatigue, anxiety, stress, sadness, and agitation were significantly lower, and ratings of happiness, energy levels, relaxation, and calmness were significantly higher after a single Reiki session. Conclusion The results of this study suggest that Reiki is feasible and could be fit into the flow of clinical care in an outpatient behavioral health clinic. It improved positive emotions and feelings and decreased negative measures. Implementing Reiki in clinical practice should be further explored to improve mental health and well-being.
Virtual Reality Simulation to Improve Postoperative Cardiothoracic Surgical Patient Outcomes
Anderson, Robert J., Haney, Rory M., Reisdorf, Emily M., Baalson, Kiersten, Bauer, Philippe R. , Arghami, Arman

Mayo Clinic

American Journal of Critical Care | March 1, 2025 | Volume: 34 | Issue: 2 | Pages: 111-118

10.4037/ajcc2025704 | PMID 40021355 Get It

Background Patients undergoing medical procedures benefit from preprocedural education. Objective To evaluate a multisensory virtual reality preoperative educational program for patients undergoing elective cardiovascular surgical procedures with postoperative recovery in the intensive care unit (ICU) and assess its impact on patients’ outcomes and experience. Methods Patients scheduled for elective cardiovascular surgical procedures with expected recovery in the ICU were enrolled. A multidisciplinary team designed the virtual reality simulation. Educational objectives focused on patient safety, family presence, ICU machinery and activities, reorientation, and communication with the care team. Historical control patients (n = 94) underwent medical record review and were contacted to complete surveys. Virtual reality simulation patients (n = 44) underwent medical record review, viewed the simulation at a preoperative appointment, and completed surveys. The study included patients admitted from June 4, 2019, to May 12, 2022. Results Durations of postoperative sedation and mechanical ventilation were lower in patients receiving virtual reality simulation. Most patients in the virtual reality simulation group (92%) said the simulation alleviated their anxiety and helped them understand what to expect in the ICU. The simulation improved their feeling of safety and decreased their fear of the unknown. Delirium incidence was not different in the 2 groups. Conclusions Preprocedural education via virtual reality simulation can improve the experience and outcomes of patients undergoing elective cardiothoracic surgery with recovery in the ICU.
Escalation of Oxygenation Modalities and Mortality in Critically Ill Immunocompromised Patient With Acute Hypoxemic Respiratory Failure: A Clustering Analysis of a Prospectively Multicenter, Multinational Dataset
Yvin, Élise, Kouatchet, Achille, Mokart, Djamel, Martín‐Loeches, Ignacio , Seguin, Amélie, Louw, Andry van de, Mabrouki, Asma, Bredin, Swann, Klouche, Kada , Mehta, Sangeeta , Bruneel, Fabrice , Lisboa, Tiago, Viana, William, Pickkers, Peter , Russell, Lene , Rusínová, Kateřina , Rello, Jordi, Clère-Jehl, Raphaël , Lafarge, Antoine , Lemiale, Virginie , Mercat, Alain , Russell, Lene , Martin-Loeches, Ignacio , Kouatchet, Achille, Mokart, Djamel , Taccone, Fabio Silvio , Pène, Frédéric , Bauer, Philippe R. , Seguin, Amélie, Metaxa, Victoria , Montini, Luca , Lisboa, Tiago, Rello, Jordi , Barbier, Francois, Azoulay, Élie , Darmon, Michaël

Mayo Clinic

Critical Care Medicine | February 27, 2025 | Volume: 53 | Issue: 5 | Pages: e1055-e1065

10.1097/ccm.0000000000006600 | PMID 40013850 Get It

OBJECTIVES: Acute hypoxemic respiratory failure in immunocompromised patients remains the leading cause of admission to the ICU, with high case fatality. The response to the initial oxygenation strategy may be predictive of outcome. This study aims to assess the response to the evolutionary profiles of oxygenation strategy and the association with survival. DESIGN: Post hoc analysis of EFRAIM study with a nonparametric longitudinal clustering technique (longitudinal K-mean). SETTING AND PATIENTS: Multinational, observational prospective cohort study performed in critically ill immunocompromised patients admitted for an acute respiratory failure. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: A total of 1547 patients who did not require invasive mechanical ventilation (iMV) at ICU admission were included. Change in ventilatory support was assessed and three clusters of change in oxygenation modality over time were identified. Cluster A: 12.3% iMV requirement and high survival rate, n = 717 patients (46.3%); cluster B: 32.9% need for iMV, 97% ICU mortality, n = 499 patients (32.3%); and cluster C: 37.5% need for iMV, 0.3% ICU mortality, n = 331 patients (21.4%). These clusters demonstrated a high discrimination. After adjustment for confounders, clusters B and C were independently associated with need for iMV (odds ratio [OR], 9.87; 95% CI, 7.26–13.50 and OR, 19.8; 95% CI, 13.7–29.1). CONCLUSIONS: This study identified three distinct highly performing clusters of response to initial oxygenation strategy, which reliably predicted the need for iMV requirement and hospital mortality.
Composition and Priorities of Multidisciplinary Pediatric Thyroid Programs: A Consensus Statement
Kothari, R. , Donner, Julia R. , Balakrishnan, Karthik , Hartman, Gary E. , Workgroup:, Pediatric Thyroid Program, Antal, Zoltan , Chelius, Daniel C. , Cherella, Christine E. , Dahl, John P. , Dimachkieh, Amy L. , Fox, Larry A. , Helmig, Sara , Kazahaya, Ken , Laetsch, Theodore W. , Mahajan, Priya , Parsons, Lauren , Quintanilla‐Dieck, Lourdes, Simons, Jeffrey S. , Sheyn, Anthony , Wagner, Amy J., Seeley, Hilary, Meister, Kara D. , Bauer, Andrew J , Cherella, Christine , Mahajan, Priya , Wasserman, Jonathan D , Wassner, Ari J , Meister, Kara D , Balakrishnan, Karthik , Kothari, Ronik, Workgroup:, Pediatric Thyroid Program, Alazraki, Adina , Jiang, Wen Jun , Lodish, Maya Beth , Prickett, Kara K. , Rastatter, Jeffrey C. , Rothstein, David H. , Simons, Jeffrey, Wagner, Amy, Waguespack, Steven G.

Mayo Clinic

Thyroid® | February 14, 2025 | Volume: 35 | Issue: 4 | Pages: 346-356

10.1089/thy.2024.0496 | PMID 39950999 Get It

Background: The incidence of pediatric thyroid cancer has been increasing, and care varies due to socioeconomic disparities or differing practice patterns. Clinical guidelines call for care in multidisciplinary teams to minimize variance and provide protocols. Based on expert opinion, we hope to describe the form and function of such multidisciplinary teams for pediatric thyroid programs. Methods: A modified Delphi method to reach consensus statements over two rounds. Twenty-one experts with varying backgrounds responded to each statement on a 9-point Likert scale. Upon completion of the survey, the panel reviewed and shared the results and comments from participants and modified the statements accordingly. This process was repeated such that statements reached consensus, were deemed no consensus, or had no change in the mean. Results: There was an 88% and 83% completion rate for Rounds 1 and 2, respectively. A consensus was observed that there is a distinct definable model of care for pediatric thyroid patients. No consensus was reached for the age range of patients, but programs should care for children with medullary thyroid cancer, differentiated thyroid cancer, and patients with genetic predisposition syndromes. A comprehensive team includes, but is not limited to, a thyroid surgeon, a pediatric endocrinologist, a high-volume fine-needle aspiration (FNA) proceduralist, an oncologist, a nuclear medicine physician, a pediatric pathologist, a pediatric radiologist, and a nurse coordinator. Necessary support services involve care coordination, access to a multidisciplinary tumor board, ability to perform ultrasound-guided FNA, and access to molecular testing. The panel emphasized cross-institutional collaborative research prioritizing guidelines development, disease-specific outcomes, treatment toxicity, and the molecular landscape of thyroid cancer. Conclusions: These consensus statements can be beneficial in improving multidisciplinary care, by describing which elements of pediatric thyroid programs should be consistent across institutions. Overall, the panel agreed that pediatric thyroid centers should provide integrated care with defined team members, services, resources, and research priorities. This model has the potential to standardize various aspects of clinical care and enhance our ability to study patient outcomes, improve health care delivery, and increase scholarly collaboration.